Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christopher J Sweeney, M.B.,B.S.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA208254 (SWEENEY, CHRISTOPHER J) Aug 15, 2016 - Jul 31, 2019
    NIH/NCI
    Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
    Role: Principal Investigator
  2. R03CA156048 (SWEENEY, CHRISTOPHER J) Dec 1, 2010 - May 30, 2013
    NIH/NCI
    Evaluating a parthenolide analogue as a new bladder and kidney cancer therapy
    Role: Principal Investigator
  3. U54CA156732 (VISWANATH, KASISOMAYAJULA) Sep 27, 2010 - Aug 31, 2021
    NIH/NCI
    2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
    Role: Co-Principal Investigator
  4. M01RR000750 (BRATER, D CRAIG) Dec 1, 1976 - Nov 30, 2009
    NIH/NCRR
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019 Jun 02. PMID: 31157964.
    Citations:    
  2. Morel KL, Ormsby RJ, Klebe S, Sweeney CJ, Sykes PJ. DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo. Radiat Res. 2019 May 16. PMID: 31095445.
    Citations:    
  3. Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 Jun; 114:107-116. PMID: 31082669.
    Citations:    
  4. Stoneham S, Murray M, Thomas B, Williamson M, Sweeney C, Frazier L. AYA testis cancer: The unmet challenge. Pediatr Blood Cancer. 2019 Aug; 66(8):e27796. PMID: 31066223.
    Citations:    
  5. Sweeney CJ, De Abreu Lourenco R, Hamid AA, Buyse M. What Does Metastasis-Free Survival Actually Mean? J Clin Oncol. 2019 Jul 01; 37(19):1679-1680. PMID: 31050909.
    Citations:    
  6. Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. Eur J Cancer. 2019 Jun; 114:128-136. PMID: 31060925.
    Citations:    
  7. McKay R, Mills H, Werner L, Choudhury A, Choueiri T, Jacobus S, Pace A, Polacek L, Pomerantz M, Prisby J, Sweeney C, Walsh M, Taplin ME. Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. J Med Internet Res. 2019 May 02; 21(5):e12044. PMID: 31045501.
    Citations:    
  8. McGregor BA, Miller RE, O'Donnell E, Albiges LK, Sweeney CJ, Markt SC. Body Mass Index and Outcomes in Germ-Cell Tumors. Clin Genitourin Cancer. 2019 Apr 25. PMID: 31129146.
    Citations:    
  9. Sweeney CJ. Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer. Eur Urol Focus. 2019 03; 5(2):111-113. PMID: 30898552.
    Citations:    
  10. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 Apr; 20(4):518-530. PMID: 30857956.
    Citations:    
  11. Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, van Andel G, Clarke NW, Hulshof MC, James ND, Parker CC, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Verhagen PC, Tierney JF. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019 Jul; 76(1):115-124. PMID: 30826218.
    Citations:    
  12. Vapiwala N, Hofman MS, Murphy DG, Williams S, Sweeney C. Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. J Clin Oncol. 2019 Apr 01; 37(10):765-769. PMID: 30794477.
    Citations:    
  13. Prast-Nielsen S, Tobin AM, Adamzik K, Powles A, Hugerth LW, Sweeney C, Kirby B, Engstrand L, Fry L. Investigation of the skin microbiome: swabs vs. biopsies. Br J Dermatol. 2019 Jan 28. PMID: 30693476.
    Citations:    Fields:    
  14. AlDubayan SH, Pyle LC, Gamulin M, Kulis T, Moore ND, Taylor-Weiner A, Hamid AA, Reardon B, Wubbenhorst B, Godse R, Vaughn DJ, Jacobs LA, Meien S, Grgic M, Kastelan Z, Markt SC, Damrauer SM, Rader DJ, Kember RL, Loud JT, Kanetsky PA, Greene MH, Sweeney CJ, Kubisch C, Nathanson KL, Van Allen EM, Stewart DR, Lessel D. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncol. 2019 Jan 24. PMID: 30676620.
    Citations:    Fields:    
  15. Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019 Jan 14. PMID: 30643173.
    Citations:    Fields:    
  16. Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019 Jul; 76(1):89-97. PMID: 30553611.
    Citations:    
  17. Withington J, Cole AP, Meyer CP, Seisen T, Schmid M, Lipsitz SR, Sweeney CJ, Dasgupta P, Trinh QD. Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU Int. 2019 Mar; 123(3):385-387. PMID: 30536825.
    Citations:    Fields:    
  18. McKay RR, Werner L, Jacobus SJ, Jones A, Mostaghel EA, Marck BT, Choudhury AD, Pomerantz MM, Sweeney CJ, Slovin SF, Morris MJ, Kantoff PW, Taplin ME. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019 Feb 15; 125(4):524-532. PMID: 30427533.
    Citations:    Fields:    
  19. Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Mar; 28(3):584-590. PMID: 30420441.
    Citations:    Fields:    
  20. Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ. Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clin Genitourin Cancer. 2019 Feb; 17(1):32-37. PMID: 30348512.
    Citations:    Fields:    
  21. Tosco L, Briganti A, D'amico AV, Eastham J, Eisenberger M, Gleave M, Haustermans K, Logothetis CJ, Saad F, Sweeney C, Taplin ME, Fizazi K. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. Eur Urol. 2019 01; 75(1):44-60. PMID: 30286948.
    Citations:    Fields:    
  22. Howard SA, Rosenthal MH, Qin L, Matalon SA, Bernard BD, Beard CJ, Sweeney CJ. Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors. Am J Clin Oncol. 2018 10; 41(10):949-952. PMID: 28654572.
    Citations:    Fields:    
  23. Hamid AA, Markt SC, Vicier C, McDermott K, Richardson P, Ho VT, Sweeney CJ. Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clin Genitourin Cancer. 2019 Feb; 17(1):58-64.e1. PMID: 30309761.
    Citations:    Fields:    
  24. Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 02; 75(2):285-293. PMID: 30119985.
    Citations:    Fields:    
  25. Sweeney CJ. Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next? Eur Urol. 2018 10; 74(4):420-421. PMID: 30007817.
    Citations:    Fields:    Translation:Humans
  26. Reynolds PS, Fisher BJ, McCarter J, Sweeney C, Martin EJ, Middleton P, Ellenberg M, Fowler E, Brophy DF, Fowler AA, Spiess BD, Natarajan R. Interventional vitamin C: A strategy for attenuation of coagulopathy and inflammation in a swine multiple injuries model. J Trauma Acute Care Surg. 2018 Jul; 85(1S Suppl 2):S57-S67. PMID: 29538225.
    Citations: 2     Fields:    
  27. Morel KL, Ormsby RJ, Solly EL, Tran LNK, Sweeney CJ, Klebe S, Cordes N, Sykes PJ. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 10; 35(7):649-661. PMID: 29936575.
    Citations:    Fields:    
  28. Choudhury AD, Gray KP, Supko JG, Harshman LC, Taplin ME, Pace AF, Farina M, Zukotynski KA, Bernard B, Kantoff PW, Pomerantz M, Sweeney C. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07. PMID: 29882250.
    Citations:    
  29. Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest. 2018 Jul 02; 128(7):2979-2995. PMID: 29863497.
    Citations:    Fields:    
  30. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Reply to J.J. Tao et al. J Clin Oncol. 2018 Aug 10; 36(23):2451. PMID: 29856693.
    Citations:    Fields:    
  31. Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Rydzewska LH, Sweeney CJ, Spears MR, Sydes MR, Tierney JF. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018 May 01; 29(5):1249-1257. PMID: 29788164.
    Citations:    Fields:    
  32. Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 May; 131(5):517-523. PMID: 29555248.
    Citations:    Fields:    
  33. Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol. 2018 Apr 10; 36(11):1088-1095. PMID: 29522362.
    Citations: 1     Fields:    
  34. Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018 06; 73(6):847-855. PMID: 29475737.
    Citations: 2     Fields:    
  35. Deraska PV, O'Leary C, Reavis HD, Labe S, Dinh TK, Lazaro JB, Sweeney C, D'Andrea AD, Kozono D. NF-?B inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. Cell Death Discov. 2018 Dec; 4:10. PMID: 29531807.
    Citations:    
  36. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10; 36(11):1080-1087. PMID: 29384722.
    Citations: 8     Fields:    
  37. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018 Feb 20; 36(6):536-542. PMID: 29320312.
    Citations: 10     Fields:    
  38. Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clin Genitourin Cancer. 2018 04; 16(2):130-134. PMID: 29331381.
    Citations:    Fields:    
  39. Xie W, Regan MM, Sweeney CJ. Reply to Y. Zhu et al. J Clin Oncol. 2018 Feb 10; 36(5):515-516. PMID: 29267131.
    Citations:    Fields:    
  40. Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018 03; 25(3):220-231. PMID: 29266472.
    Citations: 4     Fields:    
  41. Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 02 01; 36(4):376-382. PMID: 29261442.
    Citations: 1     Fields:    
  42. McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer Prostatic Dis. 2018 09; 21(3):306-318. PMID: 29263421.
    Citations:    Fields:    Translation:Humans
  43. Harshman LC, Xie W, Moreira RB, Bossé D, Ruiz Ares GJ, Sweeney CJ, Choueiri TK. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. Cancer. 2018 Mar 01; 124(5):925-933. PMID: 29266178.
    Citations: 2     Fields:    
  44. Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018 02; 23(2):193-202. PMID: 29183960.
    Citations: 1     Fields:    
  45. Dorff TB, Sweeney CJ. Chemotherapy for oligometastatic prostate cancer. Curr Opin Urol. 2017 Nov; 27(6):553-558. PMID: 28817399.
    Citations: 1     Fields:    Translation:Humans
  46. Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Kanigel Winner K, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC. A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer. JCO Clin Cancer Inform. 2017 11; 1:1-15. PMID: 30657384.
    Citations:    
  47. Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res. 2017 Nov 15; 23(22):7072-7083. PMID: 28899973.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  48. Rowson-Hodel AR, Wald JH, Hatakeyama J, O'Neal WK, Stonebraker JR, VanderVorst K, Saldana MJ, Borowsky AD, Sweeney C, Carraway KL. Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene. 2018 01 11; 37(2):197-207. PMID: 28892049.
    Citations:    Fields:    Translation:HumansAnimalsCells
  49. Wong SE, North SA, Sweeney CJ, Stockler MR, Sridhar SS. Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clin Genitourin Cancer. 2017 Sep 08. PMID: 28993132.
    Citations:    Fields:    
  50. Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017 09 20; 35(27):3097-3104. PMID: 28796587.
    Citations: 5     Fields:    Translation:Humans
  51. Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 10; 84:88-101. PMID: 28800492.
    Citations: 7     Fields:    Translation:Humans
  52. Hamid AA, Sweeney CJ. Prostate cancer: A new standard-of-care for advanced-stage disease. Nat Rev Clin Oncol. 2017 10; 14(10):592-593. PMID: 28786417.
    Citations:    Fields:    
  53. O'Donnell E, Markt SC, Miller R, Bernard B, Albiges L, Beard C, Sweeney C. Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. Clin Genitourin Cancer. 2017 Aug 03. PMID: 28851592.
    Citations:    Fields:    
  54. Pezaro CJ, Omlin A, Mastris K, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Ann Oncol. 2017 08 01; 28(8):1692-1694. PMID: 28838209.
    Citations: 1     Fields:    Translation:Humans
  55. Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311. PMID: 28762529.
    Citations: 2     Fields:    Translation:HumansCells
  56. Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, Allemani C. Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413]. Gynecol Oncol. 2017 12; 147(3):726. PMID: 28687170.
    Citations:    Fields:    
  57. Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C. Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404]. Gynecol Oncol. 2017 12; 147(3):725. PMID: 28688523.
    Citations:    Fields:    
  58. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. PMID: 28655541.
    Citations: 19     Fields:    Translation:Humans
  59. Wald JH, Hatakeyama J, Printsev I, Cuevas A, Fry WHD, Saldana MJ, VanderVorst K, Rowson-Hodel A, Angelastro JM, Sweeney C, Carraway KL. Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination. Oncogene. 2017 09 07; 36(36):5158-5167. PMID: 28481871.
    Citations: 4     Fields:    Translation:HumansCells
  60. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104. PMID: 28453693.
    Citations: 3     Fields:    Translation:Humans
  61. Paterson C, Yew-Fung C, Sweeney C, Szewczyk-Bieda M, Lang S, Nabi G. Predictors of growth kinetics and outcomes in small renal masses (SRM =4 cm in size): Tayside Active Surveillance Cohort (TASC) Study. Eur J Surg Oncol. 2017 Aug; 43(8):1589-1597. PMID: 28365130.
    Citations:    
  62. Murphy DG, Sweeney CJ, Tombal B. "Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol. 2017 07; 72(1):1-3. PMID: 28283344.
    Citations: 5     Fields:    Translation:Humans
  63. Morel KL, Ormsby RJ, Bezak E, Sweeney CJ, Sykes PJ. Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo. Radiat Res. 2017 05; 187(5):501-512. PMID: 28398879.
    Citations: 1     Fields:    Translation:AnimalsPHPublic Health
  64. Browne K, Divilly D, McGarry M, Sweeney C, Kelly ME. Chronic Disease Management - The Patient's Perspective. Ir Med J. 2017 Feb 10; 110(2):511. PMID: 28657256.
    Citations:    
  65. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. Racial Disparities in Prostate Cancer Outcome among Prostate-Specific Antigen Screening Eligible Populations in the United States. Ann Oncol. 2017 Feb 08. PMID: 28174838.
    Citations:    
  66. Bernard B, Muralidhar V, Chen YH, Sridhar SS, Mitchell EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 05 01; 123(9):1536-1544. PMID: 28055108.
    Citations:    Fields:    Translation:Humans
  67. Clement JM, Sweeney CJ. Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer. J Oncol Pract. 2017 01; 13(1):9-18. PMID: 28045610.